WhaleCreepWhat the best hedge funds own, from their SEC 13F filings
HomeFundsRA Capital Management › Q1 2008

RA Capital Management 13F holdings, Q1 2008

Holdings as of March 31, 2008 · filings on SEC EDGAR · latest filing →

RA Capital Management disclosed 17 US equity positions worth $134.5m in its Q1 2008 13F filing. The largest position was VRTX at 12.5% of the reported book, followed by ONYX PHARMACEUTICALS INC and NBIX. Against the Q4 2007 filing, it opened 5 new positions, added to 7 and reduced 2 among the top 17 holdings.

← Q4 2007 · Q2 2008 →

What did RA Capital Management own in Q1 2008? Top 17 positions

#StockSectorWeightValueSharesΔ sharesvs Q4 2007
1 VRTX VERTEX PHARMACEUTICALS INC Healthcare 12.5%$16.9m705,744 new
2 ONYX PHARMACEUTICALS INC 12.3%$16.5m570,000 new
3 NBIX NEUROCRINE BIOSCIENCES INC Healthcare 9.8%$13.2m2,442,000 2% added
4 MIDDLEBROOK PHARMACEUTICAL I 9.6%$12.9m3,214,650 new
5 QUESTCOR PHARMACEUTICALS INC 8.1%$10.9m2,636,767 5% added
6 CRIS CURIS INC 8.0%$10.7m7,550,564 0% held
7 ROCKWELL MEDICAL TECH 6.2%$8.4m1,366,667 0% held
8 CYPRESS BIOSCIENCES INC 5.0%$6.7m942,073 new
9 REPROS THERAPEUTICS INC 4.2%$5.7m579,806 95% added
10 JAVELIN PHARMACEUTICALS INC 3.9%$5.3m1,869,951 5% added
11 ATHERSYS INC 3.4%$4.5m1,305,295 5% added
12 SUPERGEN INC 3.3%$4.5m1,777,053 76% added
13 COUGAR BIOTECHNOLOGY INC 3.2%$4.3m204,238 28% added
14 ARDEA BIOSCIENCES INC 2.9%$3.9m301,887 0% held
15 LIPID SCIENCES INC ARIZ 2.7%$3.7m3,570,217 -4% reduced
16 PENWEST PHARMACEUTICALS CO 2.5%$3.4m1,297,650 new
17 OREXIGEN THERAPEUTICS INC 2.3%$3.2m306,843 -62% reduced

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.